Knee Osteoarthritis Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Knee Osteoarthritis Market Size - Analysis

The knee osteoarthritis market is expected to grow significantly due to the rising geriatric population worldwide and the associated increase in the prevalence of osteoarthritis. Moreover, the development and approval of novel drug classes for osteoarthritis treatment such as Intra-articular tranexamic acid are expected to provide opportunities for market growth between 2025-2032.

Knee Osteoarthritis Market Trends

As life expectancy is increasing globally, populations are aging rapidly all around the world. The geriatric population which is aged 65 years and above is growing at an unprecedented rate. It is estimated that by the year 2050 worldwide, 1 in 6 people will be aged 65 years and above. With increasing age, the tissues in the body including cartilage starts wearing down naturally. Knee osteoarthritis predominantly affects this aging population as cartilage becomes thin and even wears away with time, leading to bones rubbing together causing pain, swelling and stiffness. Older age is the single biggest risk factor for knee osteoarthritis.

Over the past decade, there have been major technological leaps in surgical procedures and medical devices for treatment of knee osteoarthritis. Minimally invasive techniques like arthroscopy are becoming increasingly popular compared to traditional open knee replacement surgeries that involve larger incisions. Arthroscopy facilitates diagnostic assessment of knee problems through tiny incisions and cameras inserted in the joint. It also allows procedures like removal of loose bone or cartilage flaps, debridement of areas inflamed by arthritis and repairs of torn ligaments or meniscus with minimal downtime.

Market Challenge - High costs associated with advanced knee osteoarthritis treatments

One major opportunity for growth in the knee osteoarthritis market lies in the development of new therapies that can address some of the unmet medical needs in knee osteoarthritis treatment. Currently available pharmacological therapies have limited efficacy in modifying the disease progression and mainly provide symptomatic relief. Further, joint replacement surgeries are highly invasive options considered only for end-stage disease. This leaves a significant need for the development of disease-modifying treatments that can slow cartilage deterioration and improve joint health. Companies are actively investing in research efforts exploring newer treatment modalities like gene therapies, cell therapies and tissue-engineered solutions that can potentially repair damaged cartilage. The success of such new treatment options in clinical trials would open up lucrative growth prospects by offering minimally invasive solutions to patients early in the disease course. Overall, the substantial unmet needs in managing the underlying pathology of osteoarthritis presents a major commercial opportunity for pharmaceutical companies and devices players in the knee osteoarthritis market.

Key winning strategies adopted by key players of Knee Osteoarthritis Market

Developing innovative treatment options has been a successful strategy for players. For example, in 2020, Smith & Nephew launched the CORI Surgical System for robot-assisted partial knee replacements. It utilizes navigation techniques for precise alignment and sizing. Early clinical studies show it improves surgical accuracy. The user-friendly robotic interface makes the procedure less invasive. This helped capture market share from traditional partial knee replacement devices.

Companies have partnered or acquired complementary firms to expand their product portfolios. For instance, in 2021, Smith+Nephew acquired Emperative to add artificial intelligence capabilities for diagnosing and treating knee osteoarthritis. AI algorithms can better detect hard-to-see bone changes which guides targeted treatment planning. This expanded S+N's offerings from surgical to pre-operative care management solutions.

Segmental Analysis of Knee Osteoarthritis Market

Insights, By Knee Osteoarthritis Treatment: Pharmacological management sub-segment contributes the highest share of the market owing to higher treatment efficacy and widespread availability

The pharmacological management sub-segment currently contributes the largest share of 58.0% in the global knee osteoarthritis market. This can be attributed to the higher efficacy demonstrated by pharmacological treatments in managing the symptoms of knee osteoarthritis such as pain and swelling. Drugs such as analgesics, NSAIDs, corticosteroids, and viscosupplementation agents have proven effective in significantly reducing pain and improving physical function and mobility in patients. Additionally, these drug therapies are non-invasive in nature and associated with a faster recovery compared to surgical options.

Insights, By Disease Type - Primary osteoarthritis sub-segment contributes the highest share of 72.3% in the market due to high prevalence among aging populations

As life expectancy continues to rise globally, the pool of aging individuals who are more susceptible to primary osteoarthritis is also growing steadily. Advanced age is considered one of the strongest risk factors for primary osteoarthritis, with nearly 70% of those over 65 years suffering from the condition in some form. The proportion of elderly people aged 60 years and above has been rising rapidly across world regions. This demographic shift is anticipated to significantly fuel the prevalence of primary osteoarthritis in the total knee osteoarthritis population over the forecast period. Additionally, factors such as obesity and joint injuries that heighten the risk of primary osteoarthritis are also becoming more widespread. These trends are expected to propel the growth of the primary osteoarthritis segment in the knee osteoarthritis market.

Additional Insights of Knee Osteoarthritis Market

• Knee osteoarthritis (OA) is a degenerative joint disease that predominantly affects the elderly, resulting from wear and tear of the cartilage. It can develop slowly over 10-15 years, significantly impacting daily activities. Current management strategies focus on symptom control, utilizing pharmacological, non-pharmacological, and surgical interventions. The market is witnessing advancements in treatment approaches, including the development of new pharmacological therapies and the adoption of minimally invasive surgeries. The United States holds the largest market share due to a higher prevalence and availability of advanced treatments.
• Among the EU4 and the UK, Germany accounted for the highest number of knee osteoarthritis cases, followed by France, with Italy accounting for the lowest cases in 2023.
• The prevalence of knee osteoarthritis is significantly higher in females (60%) compared to males (40%).
• The US has the highest number of prevalent cases of knee osteoarthritis, with approximately 18,499,200 cases in 2023.

Competitive overview of Knee Osteoarthritis Market

The major players operating in the knee osteoarthritis market include Sanofi/Genzyme, Bioventus, Anika Therapeutics, Taiwan Liposome Company (TLC599), Centrexion Therapeutics (CNTX-4975), Biosplice Therapeutics (Lorecivivint), Noven Pharmaceuticals (HP-5000) and Kolon TissueGene (Invossa TG-C).

Recent Developments in Knee Osteoarthritis Market

Knee Osteoarthritis Market Segmentation

• By Knee Osteoarthritis Treatment
  • Pharmacological Management
  • Non-Pharmacological Management
  • Surgery
• By Disease Type
  • Primary Osteoarthritis
  • Secondary Osteoarthritis